Molecular and genetic research in practice of oncology clinic

EGFR gene mutation studies with small cell lung cancer (NSCLC) and mutations in genes KRAS, NRAS in colorectal cancer (CRC) are mandatory in the appointment of targeted therapy. The study of genetic damage of BRAF is required when assigning a specific inhibitor treatment mutated kinase isoforms - vemurafenib. Inherited form of breast cancer (BC) is associated with mutations in the genes BRCA1, BRCA2 and CHEK2. BRCA mutations are considered as molecular genetic markers of prognostic value.